In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH. This episode includes discussion of: A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19 A post hoc analysis of TANGO, evaluating the virologic and met...
Sep 08, 2021•30 min•Ep. 82
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from: BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated pat...
Sep 07, 2021•16 min•Ep. 81
In this episode, Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, and Lewis R. Roberts, MB ChB, PhD, examine the HBV burden and care disparities in specific populations, including Asian Americans and foreign-born immigrants, and strategies to address barriers to care. Presenters: Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Professor of Medicine Department of Gastroenterology and Hepatology Stanford University Medical Center Palo Alto, California Lewis R. Roberts, MB ChB, PhD Professor of Medicine and Consul...
Sep 03, 2021•45 min•Ep. 79
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from: BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated pat...
Sep 02, 2021•11 min•Ep. 78
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from: BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated pat...
Sep 01, 2021•14 min•Ep. 77
In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy. Listen as he gives his perspectives on: Weight gain following ART initiation by ARV class and ARV drug Results of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetes BMI changes in PWH DHHS and IAS-USA guidelines for initial therapy Presenter: Joseph J. Eron, MD Professor of Medicine and Epidemiology University of North ...
Aug 30, 2021•14 min•Ep. 76
In this episode, David Malebranche, MD, MPH, discusses modifying ART in virologically suppressed patients, including switching ART in a patient with daily pill fatigue, switching ART to avoid comorbidities and simplifying ART in the context of known multidrug resistance. The overview will include analyses from: The ATLAS and FLAIR studies in which long-acting intramuscular CAB + RPV was initiated after initial virologic suppression with oral therapy D:A:D study data that found cumulative use of ...
Aug 25, 2021•48 min•Ep. 75
In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from: The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year period The DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/F...
Aug 25, 2021•30 min•Ep. 74
In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of: The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from...
Aug 23, 2021•53 min•Ep. 73
In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including: WHO Global Clinical Platform: COVID-19 outcomes in PWH 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO) Investigational antiretroviral use CAB LA + RPV LA in treatment-naive PWH (FLAIR) Investigational antiretroviral agents LEN (CAPELLA, CALIBRATE) ISL (P011, P016) Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix) Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief,...
Aug 19, 2021•46 min•Ep. 72
During this episode, Darrell H. S. Tan, MD, FRCPC, PhD, discusses approved and guideline-recommended oral HIV PrEP regimens and provides key insights on determining PrEP candidacy as well as important considerations for specific populations/clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals. Presenter: Darrell H. S. Tan, MD, FRCPC, PhD Associate Professor Division of Infectious Diseases University of Toronto Clinician-Scientist Division of Infectious ...
Aug 12, 2021•28 min•Ep. 71
In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making. Presenter: Anna Christina L. dela Cruz, MD Associate Professor Division of Digestive Diseases and Nutrition Depar...
Jul 28, 2021•15 min•Ep. 70
In episode 4 of an ongoing series of sharing sessions between a physician and patient, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses hepatitis B diagnosis and treatment with his patient, Mark. The conversation focuses on Mark’s missed HBV diagnosis and likely reactivation following treatment for rheumatoid arthritis and raises awareness for needed improvements to communication between multidisciplinary healthcare teams. Presenter: Geoffrey M. Dusheiko MD, FCP(SA), FRCP Emeritus Professor of...
Jul 26, 2021•24 min•Ep. 69
In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and Joseph K. Lim, MD, examine the HCV burden and care disparities in specific populations, including Black, Hispanic, Asian, American Indian, and Alaska Native persons, and strategies to address barriers to care. Oluwaseun Falade-Nwulia, MBBS, MPH Associate Professor Division of Infectious Diseases Johns Hopkins University School of Medicine Attending Division of Infectious Diseases Johns Hopkins Hospital Baltimore, Maryland Joseph K. Lim, MD...
Jul 22, 2021•45 min•Ep. 68
In this episode, Stefan Zeuzem, MD, discusses exciting new data on viral hepatitis reported at the virtual EASL 2021, including new findings on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure. Stefan Zeuzem, MD Professor of Medicine Chief , Department of Medicine I JW Goethe University Hospital Frankfurt, Germany Content based on a CME program supported by educational grants provided by AbbVie, Antios Therapeutic...
Jul 19, 2021•52 min•Ep. 67
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina R...
Jul 16, 2021•31 min•Ep. 66
In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals. Presenters: Spencer H. Durham, PharmD, BCPS, BCIDP Associate Clinical Professor of Pharmacy Practice Director ...
Jul 15, 2021•52 min•Ep. 65
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Swati Gupta and Mr. Marc Dixneuf discuss how to bro...
Jul 13, 2021•34 min•Ep. 64
In this episode, Jehan Budak, MD, discusses the use of HIV-ASSIST, a free, online, decision-support tool to inform ART selection. Jehan Budak, MD Assistant Professor Division of Allergy & Infectious Diseases University of Washington Seattle, Washington Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Theratechnologies; and ViiV Healthcare. Link to full program: https://bit.ly/33RZ9Zy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for i...
Jul 08, 2021•44 min•Ep. 61
In this episode, Latesha Elopre, MD, MSPH, explains how to initiate pre-exposure prophylaxis (PrEP), including in underserved communities, with examples on overcoming barriers and improving access. Listen as she gives her perspectives on: Evidence for PrEP efficacy in the DISCOVER study Recommendations in MSM, heterosexual men and women, injection drug users, and adolescents and adults weighing more than 77 lb CDC guidance How PrEP is underused, including racial/ethnic disparities Strategies to ...
Jul 07, 2021•22 min•Ep. 63
In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of: ATLAS and FLAIR studies of long-acting injectable CAB + RPV ATLAS 2M dosing study FDA approval and DHHS statement on use of long-acting injectable ART Studies on whether an oral lead-in is needed Presenter: Dan...
Jul 07, 2021•16 min•Ep. 62
In this episode, Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, share insights on HIV antiretroviral therapy safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs as well as the latest updates and recommendations on dolutegravir and pregnancy. Joseph J. Eron, Jr., MD Professor of Medicine and Epidemiology University of North Carolina School of Medicine Director , AIDS Clinical Trials Unit University of North Carolina Chapel Hill, North Caro...
Jul 06, 2021•41 min•Ep. 60
Listen to expert insights from Joseph J. Eron, Jr., MD, on exciting data about investigational agents (dapivirine ring, islatravir, lenacapavir, broadly neutralizing antibodies) for next-generation HIV prevention. Joseph J. Eron, Jr., MD Professor of Medicine and Epidemiology University of North Carolina School of Medicine Director , AIDS Clinical Trials Unit University of North Carolina Chapel Hill, North Carolina Link to full program: https://bit.ly/3ux6FF8 Hosted by Simplecast, an AdsWizz com...
Jun 30, 2021•16 min•Ep. 59
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss wha...
Jun 18, 2021•28 min•Ep. 53
In this episode, David A. Wohl, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV. David A. Wohl, MD Professor of Medicine School of Medicine Site Leader , AIDS Clinical Trials Unit-Chapel Hill University of North Carolina at Chapel Hill Director , North Carolina AIDS Training and Education Center Chapel Hill, North Carolina Co-Director , HIV Services North Carolina Department of Correction Raleigh, North Carolina Li...
Jun 15, 2021•17 min•Ep. 57
In this episode, Roger Bedimo, MD, MS, FACP; Princy N. Kumar, MD, FIDSA, MACP; and Brian Wood, MD, answer healthcare professionals’ most pressing questions on caring for heavily treatment–experienced patients with HIV. Faculty: Roger Bedimo, MD, MS, FACP Professor of Medicine Division of Infectious Diseases University of Texas Southwestern Medical Center Section Chief Division of Infectious Diseases Department of Internal Medicine VA North Texas Health Care System Dallas, Texas Princy N. Kumar, ...
Jun 15, 2021•37 min•Ep. 55
In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty ...
Jun 10, 2021•42 min•Ep. 56
Listen to expert insights from W. David Hardy, MD, on current options for pre-exposure prophylaxis and exciting new data on next-generation HIV prevention. W. David Hardy, MD Scientific and Medical Consultant Adjunct Clinical Professor of Medicine Division of Infectious Diseases Keck School of Medicine of USC Los Angeles, California Content based on a CME program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3ux6FF8 Hosted by Simplecast,...
Jun 02, 2021•21 min•Ep. 54
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this first episode, Dr. Linda-Gail Bekker and Ms. Maureen Luba discus...
May 20, 2021•25 min•Ep. 52
In this episode, Daniel R. Kuritzkes, MD, and Michelle S. Cespedes, MD, MS, discuss new ART data from virtual CROI 2021. Michelle S. Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Department of Medicine Icahn School of Medicine at Mount Sinai Attending Physician Mount Sinai Medical Center New York, New York Daniel R. Kuritzkes, MD Chief , Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, Massachusett...
May 18, 2021•19 min•Ep. 51
